axalimogene filolisbac

Nanocap Advaxis, Inc. (NASDAQ: ADXS) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold the FDA had imposed on the Phase 3 trial of axalimogene filolisbac, which is being tested in...